From the latest issue:
Sachar and colleagues report the long-term results of the Ranger II SFA randomized trial, comparing a low-dose paclitaxel drug-coated balloon with standard angioplasty for femoropopliteal artery stenosis.
🔗 doi.org/10.1177/1358...
#PAD #Atherosclerosis
Sachar and colleagues report the long-term results of the Ranger II SFA randomized trial, comparing a low-dose paclitaxel drug-coated balloon with standard angioplasty for femoropopliteal artery stenosis.
🔗 doi.org/10.1177/1358...
#PAD #Atherosclerosis
doi.org
November 14, 2025 at 10:01 PM
From the latest issue:
Sachar and colleagues report the long-term results of the Ranger II SFA randomized trial, comparing a low-dose paclitaxel drug-coated balloon with standard angioplasty for femoropopliteal artery stenosis.
🔗 doi.org/10.1177/1358...
#PAD #Atherosclerosis
Sachar and colleagues report the long-term results of the Ranger II SFA randomized trial, comparing a low-dose paclitaxel drug-coated balloon with standard angioplasty for femoropopliteal artery stenosis.
🔗 doi.org/10.1177/1358...
#PAD #Atherosclerosis
Early experience with paclitaxel-coated balloons shows promise for treating anterior urethral stricture disease and posterior urethral stenoses. https://is.gd/yngDh9 @SocietyGURS
November 25, 2025 at 1:32 PM
Early experience with paclitaxel-coated balloons shows promise for treating anterior urethral stricture disease and posterior urethral stenoses. https://is.gd/yngDh9 @SocietyGURS
From the latest issue: Yoshioka and colleagues share data on recurrence patterns and clinical outcomes following paclitaxel-coated balloon angioplasty in patients with femoropopliteal artery disease.
journals.sagepub.com/doi/full/10....
#PeripheralArteryDisease
journals.sagepub.com/doi/full/10....
#PeripheralArteryDisease
September 4, 2025 at 10:00 PM
From the latest issue: Yoshioka and colleagues share data on recurrence patterns and clinical outcomes following paclitaxel-coated balloon angioplasty in patients with femoropopliteal artery disease.
journals.sagepub.com/doi/full/10....
#PeripheralArteryDisease
journals.sagepub.com/doi/full/10....
#PeripheralArteryDisease
Early experience with paclitaxel-coated balloons shows promise for treating anterior urethral stricture disease and posterior urethral stenoses. https://is.gd/yngDh9 @SocietyGURS
November 25, 2025 at 1:33 PM
Early experience with paclitaxel-coated balloons shows promise for treating anterior urethral stricture disease and posterior urethral stenoses. https://is.gd/yngDh9 @SocietyGURS
Drug-Coated Balloon Keeps Coronaries Open: Paclitaxel coating blocks coronary lining cell overgrowth. #coronary #balloon #stenosis #paclitaxel #dcb #heartattack
www.instagram.com/p/C4gic7bLroi/
www.instagram.com/p/C4gic7bLroi/
Howard G. Smith MD, AM on Instagram: "Drug-Coated Balloon Keeps Coronaries Open
The first coronary balloon catheter that not only opens these critical heart-feeding arteries but helps to keep them op...
0 likes, 0 comments - drhowardsmithreports on March 14, 2024: "Drug-Coated Balloon Keeps Coronaries Open
The first coronary balloon catheter that not only open..."
www.instagram.com
March 14, 2024 at 8:46 PM
Drug-Coated Balloon Keeps Coronaries Open: Paclitaxel coating blocks coronary lining cell overgrowth. #coronary #balloon #stenosis #paclitaxel #dcb #heartattack
www.instagram.com/p/C4gic7bLroi/
www.instagram.com/p/C4gic7bLroi/
A new UC Davis breakthrough is giving fresh hope to bladder #CancerPatients. A first-in-human trial of PLZ4-coated, paclitaxel-loaded micelles shows huge promise, backed by UC Davis and the VA. Early steps, big potential. #TCSC #Bladdercancer #CancerTreatment
health.ucdavis.edu/news/headlin...
health.ucdavis.edu/news/headlin...
New drug developed at UC Davis offers hope to bladder cancer patients
UC Davis Health researchers have developed a new drug with the potential to reduce chemotherapy side effects and spare patients from bladder removal surgery.
health.ucdavis.edu
November 18, 2025 at 12:01 PM
A new UC Davis breakthrough is giving fresh hope to bladder #CancerPatients. A first-in-human trial of PLZ4-coated, paclitaxel-loaded micelles shows huge promise, backed by UC Davis and the VA. Early steps, big potential. #TCSC #Bladdercancer #CancerTreatment
health.ucdavis.edu/news/headlin...
health.ucdavis.edu/news/headlin...
Treatment with a paclitaxel-coated balloon led to better outcomes in patients with multilayer in-stent restenosis compared with conventional balloon angioplasty. ms.spr.ly/63329sumwN
August 13, 2025 at 1:00 PM
Treatment with a paclitaxel-coated balloon led to better outcomes in patients with multilayer in-stent restenosis compared with conventional balloon angioplasty. ms.spr.ly/63329sumwN
Pharmacokinetics of Paclitaxel coated DEB #MSDIN2024
December 21, 2024 at 7:04 AM
Pharmacokinetics of Paclitaxel coated DEB #MSDIN2024
Paclitaxel Drug Coated Balloon Angioplasty for Medically Refractory Intracranial Atherosclerotic Disease: A U.S. Single-Center Experience with the AGENT balloon https://www.medrxiv.org/content/10.1101/2025.09.17.25336036v1
September 23, 2025 at 2:26 AM
Paclitaxel Drug Coated Balloon Angioplasty for Medically Refractory Intracranial Atherosclerotic Disease: A U.S. Single-Center Experience with the AGENT balloon https://www.medrxiv.org/content/10.1101/2025.09.17.25336036v1
Journal Club - Paclitaxel-Coated Balloon forTreatment of Small Vessel ISR. AGENT IDE RCTl. Dr J Miao
Yale Interventional Cardiology
youtu.be/Dv9kJZSp1w0?...
Yale Interventional Cardiology
youtu.be/Dv9kJZSp1w0?...
Journal Club - Paclitaxel-Coated Balloon forTreatment of Small Vessel ISR. AGENT IDE RCTl. Dr J Miao
YouTube video by Yale Interventional Cardiology
youtu.be
January 8, 2026 at 7:32 AM
Journal Club - Paclitaxel-Coated Balloon forTreatment of Small Vessel ISR. AGENT IDE RCTl. Dr J Miao
Yale Interventional Cardiology
youtu.be/Dv9kJZSp1w0?...
Yale Interventional Cardiology
youtu.be/Dv9kJZSp1w0?...
"Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in patients with intermittent claudication (SWEDEPAD 2): a multicentre, participant-masked, registry-based, randomised controlled trial."
Publié ce jour dans @thelancet.com.
www.thelancet.com/journals/lan...
Publié ce jour dans @thelancet.com.
www.thelancet.com/journals/lan...
Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in patients with intermittent claudication (SWEDEPAD 2): a multicentre, participant-masked, registry-based, r...
In patients with Rutherford stage 1–3 peripheral artery disease undergoing infrainguinal
endovascular revascularisation, paclitaxel-coated devices did not improve disease-specific
quality of life at 1...
www.thelancet.com
September 13, 2025 at 4:23 PM
"Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in patients with intermittent claudication (SWEDEPAD 2): a multicentre, participant-masked, registry-based, randomised controlled trial."
Publié ce jour dans @thelancet.com.
www.thelancet.com/journals/lan...
Publié ce jour dans @thelancet.com.
www.thelancet.com/journals/lan...
Platelet Membrane-Coated SPION for Targeted Paclitaxel Delivery and Magnetic Hyperthermia in Cancer Therapy https://www.biorxiv.org/content/10.1101/2024.11.04.621819v1
Platelet Membrane-Coated SPION for Targeted Paclitaxel Delivery and Magnetic Hyperthermia in Cancer Therapy https://www.biorxiv.org/content/10.1101/2024.11.04.621819v1
Due to the limited therapeutic efficacy and side effects associated with conventional chemotherapy,
www.biorxiv.org
November 7, 2024 at 7:47 AM
Platelet Membrane-Coated SPION for Targeted Paclitaxel Delivery and Magnetic Hyperthermia in Cancer Therapy https://www.biorxiv.org/content/10.1101/2024.11.04.621819v1
More questions are raised over the safety of paclitaxel-coated devices in PAD, according to the SWEDEPAD 1 and 2 national registry trials presented at #ESCCongress2025. Read the full story here: www.tctmd.com/news/renewed...
Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD
What to make of the registry findings is debatable, but a mortality signal in PAD patients with claudication raised eyebrows.
www.tctmd.com
September 13, 2025 at 3:28 PM
More questions are raised over the safety of paclitaxel-coated devices in PAD, according to the SWEDEPAD 1 and 2 national registry trials presented at #ESCCongress2025. Read the full story here: www.tctmd.com/news/renewed...
NEW IN EIJ: Clinical data from the SPACIOUS trial suggested that sirolimus-coated balloons offer a safe and effective alternative to paclitaxel-coated balloons for side branch treatment in coronary bifurcation PCI.
#BifurcationPCI #DCB #InterventionalCardiology #Cardiosky
🔗 ow.ly/xL2o50VjRV3
#BifurcationPCI #DCB #InterventionalCardiology #Cardiosky
🔗 ow.ly/xL2o50VjRV3
March 18, 2025 at 1:58 PM
NEW IN EIJ: Clinical data from the SPACIOUS trial suggested that sirolimus-coated balloons offer a safe and effective alternative to paclitaxel-coated balloons for side branch treatment in coronary bifurcation PCI.
#BifurcationPCI #DCB #InterventionalCardiology #Cardiosky
🔗 ow.ly/xL2o50VjRV3
#BifurcationPCI #DCB #InterventionalCardiology #Cardiosky
🔗 ow.ly/xL2o50VjRV3
🦵 Paclitaxel-based endovascular devices (drug-coated balloons and drug-eluting stents) are widely used in chronic limb-threatening ischaemia (CLTI), but concerns have persisted about increased mortality
January 8, 2026 at 9:45 AM
🦵 Paclitaxel-based endovascular devices (drug-coated balloons and drug-eluting stents) are widely used in chronic limb-threatening ischaemia (CLTI), but concerns have persisted about increased mortality
Applications and challenges of paclitaxel- coated balloons beyond coronary atherosclerotic heart disease
Applications and challenges of paclitaxel- coated balloons beyond coronary atherosclerotic heart disease - PubMed
Although drug-coated balloons (DCBs) were initially used for treating peripheral vascular diseases, with the growing popularity of the implant-free concept, they have gained increasing attention as a novel therapeutic strategy for coronary atherosclerotic heart disease. The clinical application scop …
pubmed.ncbi.nlm.nih.gov
December 1, 2025 at 8:02 PM
Applications and challenges of paclitaxel- coated balloons beyond coronary atherosclerotic heart disease
Successful Treatment of Recurrent #AirwayStenosis With #Paclitaxel-Coated Balloons: A Case Report
onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com/doi/10.1002/...
July 10, 2025 at 2:01 AM
Successful Treatment of Recurrent #AirwayStenosis With #Paclitaxel-Coated Balloons: A Case Report
onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com/doi/10.1002/...
Why did we choose paclitaxel for our AGENT™ DCB design? For higher drug transfer. Learn more: qrco.de/bgUugT
AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: qrco.de/AGENT1
AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: qrco.de/AGENT1
December 16, 2025 at 4:31 PM
Why did we choose paclitaxel for our AGENT™ DCB design? For higher drug transfer. Learn more: qrco.de/bgUugT
AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: qrco.de/AGENT1
AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: qrco.de/AGENT1
Mid-term outcomes of paclitaxel-coated balloon for de novo non-small coronary lesions: a pooled analysis
->BMC Medicine | More from Lil Dr Glen EcoChat at BigEarthData.ai
->BMC Medicine | More from Lil Dr Glen EcoChat at BigEarthData.ai
Mid-term outcomes of paclitaxel-coated balloon for de novo non-small coronary lesions: a pooled analysis
In the current study, we found that in the real-world cohort of patients with de novo non-small coronary lesions, DCB-only angioplasty was associated with significantly higher rates of DoCE and TLR compared to DES implantation at 3 years, supporting the...
bmcmedicine.biomedcentral.com
November 2, 2025 at 1:52 AM
Interested in learning about paclitaxel-coated balloon dilation for treating urethral stricture disease (#USD)? 🎈
Watch the new procedural video! 📽️ bjui.pub/Balloon-Dila...
#Urology
Watch the new procedural video! 📽️ bjui.pub/Balloon-Dila...
#Urology
May 22, 2025 at 8:07 AM
Interested in learning about paclitaxel-coated balloon dilation for treating urethral stricture disease (#USD)? 🎈
Watch the new procedural video! 📽️ bjui.pub/Balloon-Dila...
#Urology
Watch the new procedural video! 📽️ bjui.pub/Balloon-Dila...
#Urology
Paclitaxel Drug-coated Balloon Angioplasty for De Novo Coronary Lesions in an Expanded Real World Clinical Setting: The Multicenter ALLIANCE Registry https://www.medrxiv.org/content/10.64898/2025.11.30.25341329v1
December 3, 2025 at 4:55 PM
Paclitaxel Drug-coated Balloon Angioplasty for De Novo Coronary Lesions in an Expanded Real World Clinical Setting: The Multicenter ALLIANCE Registry https://www.medrxiv.org/content/10.64898/2025.11.30.25341329v1
Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis: The AGENT IDE Randomized Clinical Trial #medsky
…a Top Viewed this week at JAMA
ja.ma/6756
…a Top Viewed this week at JAMA
ja.ma/6756
March 14, 2024 at 7:18 PM
Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis: The AGENT IDE Randomized Clinical Trial #medsky
…a Top Viewed this week at JAMA
ja.ma/6756
…a Top Viewed this week at JAMA
ja.ma/6756
Platelet Membrane-Coated SPION for Targeted Paclitaxel Delivery and Magnetic Hyperthermia in Cancer Therapy https://www.biorxiv.org/content/10.1101/2024.11.04.621819v1
Platelet Membrane-Coated SPION for Targeted Paclitaxel Delivery and Magnetic Hyperthermia in Cancer Therapy https://www.biorxiv.org/content/10.1101/2024.11.04.621819v1
Due to the limited therapeutic efficacy and side effects associated with conventional chemotherapy,
www.biorxiv.org
November 7, 2024 at 7:47 AM
Platelet Membrane-Coated SPION for Targeted Paclitaxel Delivery and Magnetic Hyperthermia in Cancer Therapy https://www.biorxiv.org/content/10.1101/2024.11.04.621819v1
Online First!
Sachar and colleagues report the long-term results of the Ranger II SFA randomized trial, comparing a low-dose paclitaxel drug-coated balloon with standard angioplasty for femoropopliteal artery stenosis.
🔗 doi.org/10.1177/1358...
#PAD #Atherosclerosis
Sachar and colleagues report the long-term results of the Ranger II SFA randomized trial, comparing a low-dose paclitaxel drug-coated balloon with standard angioplasty for femoropopliteal artery stenosis.
🔗 doi.org/10.1177/1358...
#PAD #Atherosclerosis
doi.org
October 7, 2025 at 10:30 PM
Online First!
Sachar and colleagues report the long-term results of the Ranger II SFA randomized trial, comparing a low-dose paclitaxel drug-coated balloon with standard angioplasty for femoropopliteal artery stenosis.
🔗 doi.org/10.1177/1358...
#PAD #Atherosclerosis
Sachar and colleagues report the long-term results of the Ranger II SFA randomized trial, comparing a low-dose paclitaxel drug-coated balloon with standard angioplasty for femoropopliteal artery stenosis.
🔗 doi.org/10.1177/1358...
#PAD #Atherosclerosis
"Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in chronic limb-threatening ischaemia (SWEDEPAD 1): a multicentre, participant-masked, registry-based, randomised controlled trial."
Publié ce jour dans @thelancet.com.
www.thelancet.com/journals/lan...
Publié ce jour dans @thelancet.com.
www.thelancet.com/journals/lan...
Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in chronic limb-threatening ischaemia (SWEDEPAD 1): a multicentre, participant-masked, registry-based, random...
In patients with chronic limb-threatening ischaemia undergoing infrainguinal endovascular
revascularisation, paclitaxel-coated devices did not reduce major ipsilateral amputations.
www.thelancet.com
September 13, 2025 at 4:22 PM
"Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in chronic limb-threatening ischaemia (SWEDEPAD 1): a multicentre, participant-masked, registry-based, randomised controlled trial."
Publié ce jour dans @thelancet.com.
www.thelancet.com/journals/lan...
Publié ce jour dans @thelancet.com.
www.thelancet.com/journals/lan...